# AEBP1

Source: https://onco.cc/targets/aebp1/  
OnCo record `aebp1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AEBP1 (Adipocyte enhancer-binding protein 1) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Melanoma.

## Summary

As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix. May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Vemurafenib.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: AE binding protein 1; Adipocyte enhancer-binding protein 1
- Tags: cancer-genes-wave
- Symbol: AEBP1
- Class: transcription
- Biology: As a positive regulator of collagen fibrillogenesis, it is probably involved in the organisation and remodeling of the extracellular matrix. May positively regulate MAP-kinase activity in adipocytes, leading to enhanced adipocyte proliferation and reduced adipocyte differentiation. May also positively regulate NF-kappa-B activity in macrophages by promoting the phosphorylation and subsequent degradation of I-kappa-B-alpha (NFKBIA), leading to enhanced macrophage inflammatory responsiveness. Can act as a transcriptional repressor. Location: Secreted; Cytoplasm; Nucleus (UniProt). Locus 7p13 (HGNC).
- Where found: Melanoma: CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:303: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:303
- UniProt Q8IUX7: https://www.uniprot.org/uniprotkb/Q8IUX7/entry
- NCBI Gene 165: https://www.ncbi.nlm.nih.gov/gene/165
- Ensembl ENSG00000106624: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000106624

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/)
- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)

---
JSON: https://onco.cc/api/v1/entities/aebp1.json